Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Inhibrx is a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates, primarily in oncology. The company utilizes proprietary modular protein engineering platforms. Key pipeline assets include ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OX40 agonist.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(33,441) | $(43,311) |
| Net Loss Per Share (Basic & Diluted) | $(2.15) | $(2.80) |
| Total Operating Expenses | $30,927 | $42,901 |
| Research & Development (R&D) | $25,217 | $36,877 |
| General & Administrative (G&A) | $5,710 | $6,024 |
| Cash and Cash Equivalents (End of Period) | $161,657 | $216,520 |
| Long-Term Debt (Net) | $174,994 | $100,559 |
| Accumulated Deficit | $(279,628) | $(149,443) |
Liquidity: As of March 31, 2026, the company held $161.7 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least 12 months from the filing date.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $9.9 million (23%) to $33.4 million, driven primarily by a $11.7 million reduction in operating expenses.
- R&D Expense Decline: R&D expenses dropped 32% to $25.2 million. This was due to a $4.1 million decrease in clinical trial costs (ozekibart chondrosarcoma trial nearing enrollment completion) and a $6.5 million decrease in contract manufacturing costs.
- Debt Expansion: Long-term debt increased significantly from $100.6 million to $175.0 million. This reflects the March 18, 2026, amendment to the 2025 Loan Agreement, which provided an additional $75.0 million in Term B loans.
- Interest Expense: Interest expense increased by $0.8 million (30%) to $3.5 million due to the higher principal balance and amortization of debt discounts.
- Stockholders' Equity: Total stockholders' equity turned negative, moving from a surplus of $8.0 million in Q4 2025 to a deficit of $21.0 million in Q1 2026, primarily due to the net loss for the period.
Guidance, Outlook, and Risks
Management Commentary and Pipeline Updates
- Ozekibart (INBRX-109):
- Chondrosarcoma: Submitted a Biologics License Application (BLA) to the FDA in April 2026 following a successful registrational trial showing a 52% reduction in risk of disease progression.
- Colorectal Cancer: Interim data showed a 20% objective response rate (ORR) in combination with FOLFIRI. Plans to meet with the FDA in H2 2026 regarding an accelerated pathway.
- Ewing Sarcoma: Interim data showed a 64.5% ORR. Enrollment expected to complete in H2 2026.
- INBRX-106: Positive interim results announced in May 2026 for the HexAgon Phase 2 study in Head and Neck Squamous Cell Carcinoma (HNSCC), showing a 44% ORR in the combination arm vs. 21.4% in the control arm. Phase 3 initiation planned for Q3 2026.
Risks and Contingencies
- Capital Requirements: The company expects to continue incurring significant losses. Future funding will be required via equity offerings, debt financings, or strategic collaborations. Failure to secure funding could force spending reductions or program delays.
- Debt Covenants: The Amended 2025 Loan Agreement includes a minimum liquidity threshold covenant of $40.0 million. The company is currently in compliance.
- Regulatory Risk: No assurance that the BLA for ozekibart or future regulatory filings will result in approval. Clinical trial results may not be sustained.
- Forward-Looking Statements: The filing contains numerous forward-looking statements regarding clinical timelines, regulatory approvals, and financial projections, which are subject to significant risks and uncertainties.
Investor Verification Checklist
- BLA Status: Verify the current status of the ozekibart Biologics License Application submitted in April 2026 and any FDA feedback received.
- Debt Terms: Review the specific covenants and prepayment penalties in the Amended 2025 Loan Agreement, particularly the 9.0% final payment fee and interest-only period ending February 2028.
- Cash Burn Rate: Monitor the quarterly cash burn rate against the $161.7 million cash balance to validate the 12-month liquidity runway.
- Clinical Milestones: Track the initiation of the Phase 3 HexAgon study (planned Q3 2026) and the FDA meeting for ozekibart in colorectal cancer (planned H2 2026).
- Equity Dilution: Assess the impact of outstanding warrants (Oxford Warrants and pre-funded warrants) and stock options on future share count and dilution.